SynthesisScientific reports2025
Mesenchymal stromal cells in management of steroid refractory acute graft vesrus host disease, systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft versus host disease (GVHD) is a major drawback for haematopoietic stem cell transplant (SCT). Steroids are the main therapy. However, steroid resistance (SR) has poor outcome. Mesenchymal stromal cells (MSCs) had been assessed in several clinical trials but no consistent results. Here we present a systematic review and meta-analysis to explore the potential role of MSCs in steroid refractory acute GVHD (SR-aGVHD). We analysed 16 trials with total of 1301 patients. Primary end points included the safety of MSCs intravenous infusion (IVI), overall response rate (ORR) and overall survival (OS). Secondary end points included complete response rate (CR), relapse rate (RR) and organ specific response. Also, we analysed effect of other variables on outcome such as conditioning intensity, GVHD severity, age of recipients and MSCs related variables. ORR was 0.61 with 95% CI 0.54-0.67, CR rate was 0.29 with a 95% CI 0.23-0.36. Regarding organ specific response, Skin-ORR was 0.73, 95% CI 0.6-0.84, Gut-ORR was 0.62, 95% CI 0.54-0.7 and Liver-ORR was 0.55, 95% CI: 0.37-0.73. No statistically significant difference between the 3 organs ORR. At a median of 12 months, OS was 0.34 with 95% CI 0.29-0.4. However, in the controlled trials OS post MSCs was comparable with the control and ratio was 1.15, 95% CI of 0.81-1.62 and P = 0.4. RR was 0.10, 95% CI 0.06-0.15. Also, RR in controlled trials was comparable between MSCs recepients and control, risk ratio was 0.62, 95% CI of 0.3-1.25 and P = 0.18. Regarding heterogeniety, we assessed effect of conditioning intensity, recepients' age, GVHD severity and MSCs related variables. ORR post "MAC" was comparable with "nMAC", P = 0.7. GVHD grade IV cohorts had ORR of 0.51 while less severe GVHD had ORR 0.66 and P = 0.006. Young age (< 50 ys) was associtaed with better ORR and OS. ORR in "young" was 0.64 while older age had ORR of 0.5 and P = 0.04. And OS in "young" was 0.41 while older cohort had OS 0.25 and P = 0.04. Regarding MSCs related variables, dose of 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.